贝达喹啉治疗特殊人群耐药结核病的安全性与有效性研究进展  

Progress on the safety and efficacy of bedaquiline for the treatment of drug-resistant tuberculosis in special populations

作　　者：张亚萍[1] 牛亚燕 唐佩军[2] Zhang Yaping;Niu Yayan;Tang Peijun(Suzhou Medical College of Soochow University,the Affiliated Infectious Diseases Hospital,Suzhou 215000,China;Department of Tuberculosis,the Fifth People′s Hospital of Suzhou,the Affiliated Infectious Diseases Hospital of Soochow University,Suzhou 215000,China)

机构地区：[1]苏州大学苏州医学院(苏州大学附属传染病医院),苏州215000 [2]苏州市第五人民医院结核科(苏州大学附属传染病医院),苏州215000

出　　处：《中华结核和呼吸杂志》2023年第6期619-624,共6页Chinese Journal of Tuberculosis and Respiratory Diseases

摘　　要：耐药结核分枝杆菌的出现对全球结核病防控构成严重威胁。2018年世界卫生组织将贝达喹啉列为MDR/RR-TB治疗的首选药物之一。贝达喹啉的上市适用人群为成人耐多药结核病和广泛耐药结核病患者,而关于贝达喹啉在儿童、青少年、孕产妇和老人等特殊耐药结核病人群中的研究较少,本文旨在对贝达喹啉治疗耐药结核病特殊人群的有效性及安全性进行综述,供同行临床应用时参考。Antimicrobial resistance in Mycobacterium tuberculosis is a serious threat to global tuberculosis(TB)control.WHO listed bedaquiline as one of the first-choice drugs for the treatment of MDR/RR-TB in 2018.Bedaquiline is marketed for adult patients with MDR-TB and XDR-TB.However,there are few studies of bedaquiline in adolescents,pregnant women,the elderly,and other special populations with drug-resistant TB.This paper aimed to review the effectiveness and safety of bedaquiline in the treatment of special populations of drug-resistant TB for the clinical use.

关 键 词：耐药结核病 耐多药结核病 特殊人群 适用人群 安全性与有效性 贝达喹啉 耐药结核分枝杆菌 孕产妇 

分 类 号：R52[医药卫生—内科学]